Iterum Therapeutics plc [NASDAQ: ITRM] loss -3.83% or -0.09 points to close at $2.26 with a heavy trading volume of 73343664 shares. The company report on February 11, 2021 that Iterum Therapeutics plc Announces Exercise of Underwriter’s Option to Purchase Additional Ordinary Shares.
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, announced that the underwriter of its previously announced underwritten public offering of ordinary shares, which closed on February 8, 2021, has exercised in full its option to purchase additional ordinary shares at the public offering price, less underwriting discounts and commissions. After giving effect to the sale of 5,217,391 additional ordinary shares in the option closing, the total number of ordinary shares sold by the Company in the offering increased to 40,000,000 shares, which resulted in aggregate net proceeds of approximately $42.1 million after deducting underwriting discounts and commissions and estimated offering expenses.
H.C. Wainwright & Co. acted as the sole book-running manager of the offering.
It opened the trading session at $2.12, the shares rose to $2.50 and dropped to $2.05, the range by which the price of stock traded the whole day. The daily chart for ITRM points out that the company has recorded 148.95% gains over the past six months. However, it is still -402.22% lower than its most recent low trading price.
If we look at the average trading volume of 20.40M shares, ITRM reached to a volume of 73343664 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Iterum Therapeutics plc [ITRM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ITRM shares is $1.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ITRM stock is a recommendation set at 3.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
RBC Capital Mkts have made an estimate for Iterum Therapeutics plc shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on June 02, 2020. The new note on the price target was released on January 21, 2020, representing the official price target for Iterum Therapeutics plc stock.
The Average True Range (ATR) for Iterum Therapeutics plc is set at 0.35
Trading performance analysis for ITRM stock
Iterum Therapeutics plc [ITRM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 69.92. With this latest performance, ITRM shares gained by 98.25% in over the last four-week period, additionally plugging by 148.95% over the last 6 months – not to mention a drop of -15.00% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ITRM stock in for the last two-week period is set at 63.67, with the RSI for the last a single of trading hit 63.44, and the three-weeks RSI is set at 63.65 for Iterum Therapeutics plc [ITRM]. The present Moving Average for the last 50 days of trading for this stock 1.26, while it was recorded at 2.23 for the last single week of trading, and 1.31 for the last 200 days.
Iterum Therapeutics plc [ITRM]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Iterum Therapeutics plc [ITRM] shares currently have an operating margin of -275732.43. Iterum Therapeutics plc’s Net Margin is presently recorded at -278729.73.
Return on Total Capital for ITRM is now -254.31, given the latest momentum, and Return on Invested Capital for the company is -283.18. Return on Equity for this stock declined to -454.48, with Return on Assets sitting at -166.85.
Reflecting on the efficiency of the workforce at the company, Iterum Therapeutics plc [ITRM] managed to generate an average of -$2,343,864 per employee. Receivables Turnover for the company is 0.04 with a Total Asset Turnover recorded at a value of 0.00.Iterum Therapeutics plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.30 and a Current Ratio set at 0.30.
Iterum Therapeutics plc [ITRM]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Iterum Therapeutics plc posted -1.59/share EPS, while the average EPS was predicted by analysts to be reported at -1.7/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 6.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ITRM.
An analysis of insider ownership at Iterum Therapeutics plc [ITRM]
There are presently around $15 million, or 15.80% of ITRM stock, in the hands of institutional investors. The top three institutional holders of ITRM stocks are: CANAAN PARTNERS X LLC with ownership of 1,733,170, which is approximately 0% of the company’s market cap and around 0.50% of the total institutional ownership; FRAZIER MANAGEMENT LLC, holding 1,538,316 shares of the stock with an approximate value of $3.48 million in ITRM stocks shares; and NEW LEAF VENTURE PARTNERS, L.L.C., currently with $3.29 million in ITRM stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Iterum Therapeutics plc stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 11 institutional holders increased their position in Iterum Therapeutics plc [NASDAQ:ITRM] by around 1,900,768 shares. Additionally, 5 investors decreased positions by around 1,323,329 shares, while 5 investors held positions by with 3,557,384 shares. The mentioned changes placed institutional holdings at 6,781,481 shares, according to the latest SEC report filing. ITRM stock had 10 new institutional investments in for a total of 1,890,813 shares, while 4 institutional investors sold positions of 1,322,649 shares during the same period.